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The Synthesis of Various Substituted 
3-Amino-7-hydroxy-2,2-dimethyltetralins 
and Their Opioid-related Activities 
David Alan Lippman 
A series of aminotetralones and aminotetralins were synthesized 
from the common intermediate F, 3-amino-2,2-dimethyl-7-methoxy-
1-tetralone. The final compounds derived from F were simple substituted 
and/or reduced analogues. The products would allow a progressive 
structure activity relationship to be drawn based on pharmacological 
testing. 
The common intermediate F was synthesized utilizing a six step 
procedure starting with p-raethoxyphenylacetic acid. The overall yield 
from the precursor to the F:HC1 was 25%. Compound F was either 
O-demethylated to form 3-amino-2,2-dimethyl-7-hydroxy-l-tetralone (I) or 
was dimethylated on the amine and subsequently O-demethylated to yield 
the 3-dimethylamino-7-hydroxy-2,2-dimethyl-l-tetralone (J). The last 
major modification was the reduction of the carbonyl group in J to a 
methylene, to produce the 3-dimethylamino-7-hydroxy-2,2~dimethyl-
tetralin (L). These final compounds I, J, and L, as well as the 
intermediates leading to them (compounds F, II, G, and K), were tested 
for opioid activity in the isolated guinea pig ileum assay as described 
by Kosterlitz. 
ili 
All of the compounds exhibited agonist activity. They generally 
fell into three groups. Compound J was the most potent, giving 1/40 the 
potency of normorphine (NM). The majority of compounds (F, H, K, and L) 
were of intermediate potency, ranging in activity from 1/500 to 1/700 
the potency of NM. The last two compounds I and G were not only the 
least potent at 1/2000 to 1/5000 that of NM, but also the least 
efficacious. In evaluation of the receptor selectivity of the compounds 
synthesized, a range of selectivity was observed. Compound J was the 
only compound which appeared to exhibit 100% of its activity through the 
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INTRODUCTION 
In medicinal chemistry, one oust have a suitable lead compound 
which may be varied or dissected structurally to upgrade potency and 
eliminate unwanted side effects. Morphine (Structure I) offered the 
best point of departure in the search for a potent analgetic agent *nh 
little or no addiction liability. 
Structure I 
Pharmacological Basis 
Literature reports on the use of opium can be traced to the 
beginnings of recorded medical history and its use may extend veil oxer 
2000 years. The isolation of the principal active ingredient from the 
opium poppy, Panaver sominiferum. was in 1805 by Sertutner (.). f.ll«d 
f ,„HPine More than a century elapsed before 
in 1832 by the isolation of codeine. 
1 
2 
Gulland & Robinson (2) determined the structure of morphine in 1925 
(Structure I). Gates & Tschudi confirmed the structure of morphine by 
completing its total synthesis in 1952 (3), Assignment of the absolute 
stereochemistry quickly followed (A). In 1898, which was 25 years prior 
to the identification of the chemical structure of morphine, the 
synthetic modification was worked out to produce heroin (the diacetyl 
derivative). During the next 25 years hydroxycodeinone and dihydro-
hydroxycodeinone (5) were prepared and are still in use today. 
Structure Activity Relationships 
The first structure activity relationship (SAR) studies of opioids 
were initiated in 1929. This early work led to the synthesis of 
approximately 150 morphine derivatives and over 300 semi-synthetic 
products (for a review see Ref. 6). This was the foundation for future 
synthetics and semi—synthetics such as metapon (7) (5-methyldihydro-
morphine), oxycodone and oxymorphone (8). 
The general SARs for Structure II are described as follows: With 
Rj = -H, R2 = -CH3 and a double bond between C-7 and C-8, substitution 
of an alpha-OH, beta-OH, =0, -OCH3 or halogen (i.e., -01) at C-6, or 
moving the double bond to C—6 and C—7, all generally increase activity 
and toxicity. 
With a double bond between C-6 and C-7 (in the C-Ring) substitution 
0f -OH at C-8 causes a decrease in activity, yet a -CI at C-8 promotes 
increased activity. With no unsaturated bonds in the C-ring, a general 
increase in activity is seen. Additional substitution of an -OH at C-14 
tfill further increase activity. Modifications of the C-ring generally 
-R| 
Structure II 
produce quantitative changes* this being an increase in potency 
proportional to an increase in side effects. Metopon and azidomorphine 
are possible exceptions, where there is an increase in activity and a 
decrease in side effects. An intact A-ring is essential for agonist 
activity, and if Rj is alkyl instead of —H (as in morphine), e.g., -CH3 
or -CH2-CH3, potency is decreased. Further substitution of the A-ring 
will decrease activity. A notable exception is acetylation (Rj = -COCH3 
and substitution of an -OCOCH3 at C-6) which results in increased 
potency (i.e., heroine). 
The nitrogen substituents (R2) confer some quantitative changes in 
activity but more significant qualitative changes such as agonist* mixed 
agonist-antagonist, or pure antagonist activity. For example, R2 
substitutions of —CH3 or —CH2—CH2~^6^5 ai*e agonists with the phenethyl 
being the more potent. When R2 = -CH2-CH=CH2, Ri = and -OH is 
4 
substituted at C-6, as well as a double bond existing between C-7 and 
C-8, the resultant compound is nalorphine which displays mixed 
agonist-antagonist activity. Pure antagonism is conferred by retaining 
f?2 as -CH2~CH=CH2 and introducing a keto at C-6 and hydroxy at C-14 as 
in naloxone. A significant increase in potency is obtained if the allyl 
group on the amine is replaced by a -CH2~<^^ , this being the case for 
naltrexone. 
It was in 1915 that Pohl (9) observed the reversal of morphine's 
respiratory depressant effects by the administration of the N-allyl 
derivative of norcodeine. In the early 1940's N-allylnormorphine 
(nalorphine) was shown to have antagonist activity. The uniqueness of 
nalorphine's pharmacology was not truly appreciated until Lasagna & 
Beecher (10) discovered in 1954 that it possessed potent analgetic 
activity in humans, and in addition is able to completely block 
morphine's effects. This raised the dichotomy of why in animal testing 
(such as the hot plate and tail flick assays) only antagonist activity 
was seen, but in man analgetic activity was significant. 
In pursuing the synthetic route initiated by Grewe in 1946 (U), 
Schnider & Grussner (12) discovered that the furan (ether linkage) ring 
of morphine (Structure I) could be eliminated and yet the molecule would 
still retain potent analgetic activity. The morphmans (Structure III) 
are compounds that are structurally related to morphine but lack the 
4,5-epoxy bridge. The N-methylmorphinan which was originally sy 
sized was evaluated to have only 20% of the analgetic potency o 
i i \ later found to exhibit 
morphine, but its levo isomer (levorphan ) 
5 
four times the potency of morphine, and is the prototype of this drug 
class (13). 
R^-N\ s 14 
Structure III 
Potent agonists can be created with an R2 substituent of phenethyl 
or p—aminophenethyl; however, this drug class was of greater interest 
because of its potential to yield mixed agonist—antagonist compounds. 
With a phenolic group on what is analogous to the A-ring of morphine, a 
zhange of the R2 substituent on the amine from -CH2~CH=CH2 (which is a 
strong antagonist) to a -CH2-<^J group causes a change in. activity to a 
strong agonist with antagonist effects. In addition this compound is 
3ble to produce hallucinations. If an -OH at C-14 is added in addition 
:o the R2 = -CH2-<^j and Rj = -H, the resultant compound has strong 
mtagonist and weak agonist effects. Substitution of R2 with 
:auses the molecule to become a strong agonist with weak antagonist 
;ffects. 
In 1955 further simplification of the morphine backbone came about 
with the removal of the "C" ring by May & Murphy (14) which produced the 
benzomorphans or benzazocines (Structure IV). In doing so the first 
analgetic to show a separation between analgesia and addiction potential 
was created. The prototypal agent (Rj = -H, R2 = -CH2CH2C5H5, R3»R4 -
-CH3) phenazocine was the first compound of this class to be studied 
extensively. 
The SARs for the benzomorphans are generally as follows: a phenolic 
substituent at the 2'-position (Rj = -OH) usually affords greater 
activity than hydrogen. Any other substituent at the 2'-position (e.g., 
NH2, NO2, F, CI) (15) has shown less.potency than the previous two. An 
R3 replacement of a beta-OH decreases the agonist activity but will 
increase the antagonist activity. If R4 is substituted with a -C5H5, 
potent analgesia is seen. With R3 a beta-CH3» and Rj ™ -OH, the 




effects in morphine-dependent monkeys. Keeping Rj - -H* a substitution 
of R2, R3 and R4 = -CH3 will show a threefold increase in potency over 
^2* ^4 = -CH3 and R3 =» -H. As in the previous discussion of opioids, 
the R2 substitution of a phenethyl group ( -CH2-CH2-C6H5) conveys a 
20-fold gain in analgetic potency over a small aliphatic group (i.e., 
-CH3). It has been shown that some benzomorphans with R2 • -£^3 in 
combination with a large substituent at R3 do display antagonist 
properties (16). 
Serendipity took a hand in one significant advance of analgetics 
when Eisleb & Schaumann (17) synthesized meperidine in 1934. This 
compound was originally proposed to be an antispasmodic. In addition to 
its antispasmotic effect, meperidine was pharmacologically seen to cause 
straub tail in rats, which is indicative of an analgetic. The activity 
was about 20% that of morphine, but of far greater importance was the 
discovery of an active analgetic that did not closely adhere to the 
phenanthrene structure of morphine. Based on this new information, 
thousands of phenylpiperidine derivatives have since been made. Some of 
these derivatives exhibited extraordinary potency [carfentanil is nearly 
18,000 times more potent than meperidine (18)] and a few of them have 
seen clinical use. The year 1940 brought about a radical simplification 
in the structure of analgetics with the synthesis of methadone, in which 
the nitrogen atom is in a totally acyclic arrangement (19). 
In the late 1960's and early 1970's, Martin et al. (20, 21 and 
references cited therein) reported active analgetic compounds which were 
aminotetralln (Structure V) derivatives. The commonly accepted 
8 
structural components necessary for analgetic activity are retained in 
the arainotetralin structure. These features are the aromatic ring, the 
quaternary C-l substitutions, the amine separated from C-l by a two 
carbon linkage, and the tertiary amine. 
Martin e.t al. (22, 23) prepared compounds where the aromatic ring 
was left unsubstituted, or where it had a methoxy or hydroxy group in 
the 7 position (as per the numbering in Structure V). 
Structure V 
The most interesting compounds of the aminotetralin series contained 
3-dimethylamino-l-phenyl substituents. The activities of the cis and 
trans diastereomers of the compound were reported from the mouse hot 
plate assay (23). When there is no substitution at the 7-position (R = 
-H), the two isomers are about equipotent and equal in activity to 
meperidine. When R = -OH, the activity of the trans isomer increased 
about 50% and that of the cis isomer increased by about 25%. This 
change in activity is consistent with the observation that the intro­
duction of an -OH group at this position causes an increase in analgetic 
activity. 
9 
Interestingly, both isomers where R «* -OCH3 were less active than 
the corresponding compounds which were unsubstituted at this position. 
This pattern of structure activity relationships does not hold in all 
the aminotetralins. In the series with 3-diraethylamino and 1,1-dimethyl 
substitutions, the order of potency for C-7 substituents is R * -H > R * 
-OCH3 _> R — -OH (20). The compound in which R = -H was reported to be 
2.5 times as potent as meperidine is the most potent of the aminotetralin 
series to date. 
In 1981 Fries & Bertelli (24) synthesized a series of amino­
tetralins lacking the phenolic hydroxyl and the quaternary C-l carbon. 
Their results suggested that the conformation about the C-l position was 
not a critical factor for. activity, although elimination about the C-l -
C—2 carbons, resulting in a double bond and a more planar compound, 
caused an eradication of agonist activity when judged by the hot plate 
assay.. The determination of the importance of this observation will 
require further investigation. 
These 3-(cyclopropyTmethyl)methylamino-l-phenyltetralins displayed 
significant agonist and antagonist activity. The fact that in prelimi­
nary studies in morphine-addicted monkeys the trans isomer did not 
precipitate withdrawals, nor did it suppress the abstinence syndrome, is 
indicative of a non—mu receptor type activity. 
Receptors 
The findings of Goldstein et al. (25) in 1971, which fathered the 
idea of specific brain opioid receptors, were confirmed two years later 
by two groups [those of Pert and Snyder (26), and Simon et al. (27)], who 
10 
explored the pharmacological repercussions of receptor occupancy. 
Several groups of investigators then pursued the search for an 
endogenous ligand, because such a ligand seemed to be a much more 
sensible receptor occupant than an exogenous alkaloid and because the 
specific distribution of opioid receptors resembled the anatomy of known 
pain pathways. 
Although Beckett & Casey (28) and Portoghese (29) had speculated on 
the nature of the opioid receptor, in 1977 Kosterlitz et al» (30) 
furthered their work by postulating that the receptor was stereospecific 
and possessed a high affinity for endogenous opioids. Two criteria were 
set in order to establish the fact that neuronal responses to opioids 
involve stereospecific opioid binding sites. The first was that naloxone 
(an antagonist) could block the effects of the agonist. The second 
criterion was the ability to display stereo-selectivity. Thus, the 
levorotatory enantiomers of most agonists mimic the actions of the 
endogenous ligands while the dextrorotatory enantiomers do not exhibit 
similar effects at the same dose (concentration). Subsequent studies 
elucidated the fact that brain preparations showed a saturable, 
stereospecific binding site with high affinity for opioid agonists and 
antagonists (31). 
Martin addressed the dichotomous nature of nalorphine from results 
of his own studies, in addition to those of many others (32-35). He 
first postulated that receptor dualism (35) was conceptually defined 
through the presence of multiple receptors or receptor redundancy, 
light of observations from further research (36, 37), the conclusion 
11 
that two receptors existed established the presence of the M-receptor 
(for morphine) and the N-receptor (for nalorphine). In studies with 
chronic spinal dogs (39-41), three clearly distinguishable syndromes 
from single dose injections of morphine, ketocyclazocine, and N-allylnor-
metazocine (SKF-10,047) were seen. Cross tolerance effects (i.e., 
whether these drugs were able to precipitate or suppress the withdrawal 
syndrome to one another) helped formulate the basic idea of the "three 
opioid receptors." Establishing the validity of several opioid receptor 
types provided a reasonable explanation for the observations of 
different pharmacological actions of analgetic compounds by their being 
either agonists, mixed agonist-antagonists, or antagonists (42). 
The three specific receptors suggested by Martin (43) to mediate 
the effects of opioids were named for the prototypic drugs which 
produced distinct effects in laboratory dogs. The receptors were named 
mu., for morphine, kappa, for ketocyclazocine, and sigma, for SKF-10,047 
(N-allylnormetazocine). 
In 1977 while investigating opioid peptides and their binding 
characteristics in in vitro assays, the research group of Lord, 
Waterfield, Hughes and Kosterlitz concluded that the receptor population 
of the guinea pig ileum and mouse vas deferens (MVD) were not identical. 
The receptor in the MVD where the enkephalins and endorphins were mainly 
exerting their activity was named the delta receptor (44). 
Receat reports have shown that the mu and delta receptors mediate 
significant effects on respiration. Most mu agonists to date are noted 
for their addiction liability. It is proposed that sigma receptors may 
12 
have a significant role in psychotic behavior. In addition, many kappa 
agonists promote some psychotic behaviors, which are believed to be 
mediated through the sigraa receptors. The delta, kappa and mu type 
receptors are proposed to be the analgetic mediating receptors, and as 
such would be the ideal receptors to optimally stimulate, if one is 
seeking analgetic agents. Of these receptor types, if specific stimu­
lation were possible, the kappa receptor would be preferable. 
The importance of knowledge about individual opioid receptors is 
that by delineating the physiological function of each receptor type and 
the selectivity of individual analgetics to bind to these receptors, 
more selective and ideally more potent analgetics may be designed. 
Endogenous opioids are peptides that are synthesized in the body 
and elicit responses similar to the morphine-like analgetics. The first 
endogenous opioids discovered, methionine and leucine enkephalin (Fig. 1), 
were separated from brain homogenates (45). They have since been found 
in other sites such as the gut, adrenal medulla and autonomic nervous 
system. Beta endorphin (Fig. 1) was originally found in the pituitary 
and has also been found in the hypothalmus (46). 
The enkephalins and endorphins show some structural similarities 
(amino acid repetition) to each other, in addition to the exogenous 
analgetics (whose SARs have been studied extensively). 
In a very broad evaluation, the endogenous opioids exhibit many of 
the same effects as the exogenous opioid agonists, although the former 
show minimal to nonexistent side effects. The significantly potent 
exogenous molecules generally are levorotatory isomers, although 
exceptions do exist (47). 
13 
Tyr-Gly-Gly-Phe-Leu (leucine enkephalin) 
Tyr-Gly-Gly-Phe-Met (methionine enkephalin) 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-
Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Val-
Lys-Asn-Ala-His-Lys-Lys-Gly-Gln (Beta endorphin) 
MHz 
i 




Amino Acid Sequence of some endogenous opioids. 
The boxed in region represents structural 
similarities to opiates. 
14 
The existence of endogenous opioid ligands has explained many facts 
that often were attributed to being "wives* tales" or psychosomatic in 
origin. A most notable example has been placebo analgesia effects 
(48). It was shown that placebos could elicit some of their effects 
through an opioid-mediated system which was reversed by a challenge of 
naloxone. The relief of pain by acupuncture was also reversed by a 
naloxone challenge (49, 50). It is interesting to note that hypnosis-
induced analgesia does not seem to be associated with opioid mediated 
analgesia, since the naloxone challenge does not reverse the analgetic 
effects that were induced (51). 
The fact that certain forms of analgesia are not mediated by 
opioids was discussed in the article by"Mayer (52) in which it was 
mentioned that some types of pain may have dual modulation by both an 
opioid and non-opioid system. This duality would account for the 
partial blockade of analgesia by naloxone. It is important to find out 
how the non-opiate system does work and to determine the mechanism of 
cortical mediation for pain based solely on perception. 
Opioid receptors and endogenous opioid peptides are found in many 
parts of the body. The most important sites for this part of the 
discussion are the ones that are in the brain and spinal cord. The 
existence of endogenous opioids and a knowledge of how they inhibit pain 
is of invaluable importance in the further understanding of analgetics. 
Because of the considerable complexity of the opioid receptors a single 
assay procedure cannot provide unequivocal results, especially with 
peptides. The mu and delta agonists have been shown to bind 
15 
preferentially (specifically) in the mouse vas deferens, but not in the 
guinea pig ileum. Mu receptors bind morphine with 10 times the affinity 
of enkephalin, and conversely delta receptors exhibit approximately 100 
times the binding affinities for enkephalins over morphine. Naloxone's 
affinity is 20-30 times greater for the mu receptor than for the delta 
receptor (44). 
In a recent research paper by Schmauss and Yaksh (52), preliminary 
observations were made which suggested that a different opioid structure 
activity relationship might exist for nociceptive stimuli of different 
modalities. They concluded that the populations of spinal opioid 
receptors modulating the cutaneous thermal response possessed distin­
guishable pharmacological characteristics which resembled those 
described as mu & delta; whereas the visceral chemical responses were 
modulated by spinal receptors with profiles having characteristics 
resembling those of mu & kappa. These observations were very important 
for subsequent evaluation of stated conclusions documenting the agonist-
antagonist nature of analgetics, since misleading results may be drawn 
.based on the screening procedure used and the desired evaluation of 
results. In addition, the partial agonists (pentazocine, buprenorphine, 
nalorphine) can readily block visceral chemical pain but are considerably 
less active on cutaneous thermal pain (54, 55). Determinations of 
receptor selectivity of pharmacological compounds (drugs) are made 
through selective utilization of chemical tools, such as antagonists, 
which were discovered a long time ago and are still used in order to 
elucidate pharmacological actions of drugs. 
16 
Narcotic Antagonists 
Opioid antagonists are usually structurally similar to the agonists. 
The exogenous or endogenous agonist exerts a positive effect (intrinsic 
activity) upon binding to the receptor. The antagonist's effect is to 
prevent the agonist's effect by occupying the receptor site itself or 
mitigating the effects of the agonist via a different point of binding. 
The result of the action of the antagonist is that the receptor fails to 
tri8ger its usual response to an agonist. Blocking the effects of 
exogenously applied opioids was not the only response that was seen with 
analgetic antagonists, since pure antagonists also seemed to elicit some 
effects on their own (when not given as a challenge to an exogenuous 
drug). It was deemed possible that the effects seen may have been due 
to the presence of an endogenous compound which was subsequently 
affected by the presence of the antagonist. From that deduction and 
work that was done in the late 1960's, it is now common knowledge that 
there are endogenous opioids. Antagonists play very important and 
instrumental roles in the differentiation and characterization of 
analgetics, their properties, expected effects and side effects, and how 
each of the receptors in turn mediates specific responses in the body. 
Because antagonists have the ability to inhibit responses of 
agonists, certain disease states have been attributed to possible 
imbalances of endogenous opioids and endogenous opioid receptors. The 
use of opioid antagonists for disease states such as septic shock 
(56-58), cardiogenic shock (56), and cerebral ischemia (59, 60) have 
been documented. Recently it has been shown that antagonists may have a 




Some forms of physical discomfort may be described as painful. 
No two persons perceive a painful stimulus in exactly the same way, and 
each person describes pain somewhat differently. Pain is perceived by 
nociceptive nerve endings located in the skin, viscera and body walls, 
and may be activated by thermal, chemical or mechanical stimuli. These 
pain impulses are transmitted by primary afferent fibers (A delta and C 
fibers) to the dorsal horn of the spinal cord (62), where complex 
interactions occur. 
The circuitry of the superficial dorsal horn is an area under active 
investigation. Studies have shown that primary afferents terminate on 
both second-order sensory projection cells (63) (such as spinothalamic 
tract cells) and intrinsic interneurons within the spinal column. There 
is experimental evidence that some of the interneurons are excitatory 
relay cells (64), whereas others are probably inhibitory or regulatory 
interneurons (65). There are numerous interneurons within this region 
which contain enkephalin—like immunoreactivity and may have an inhibitory 
function (66, 67). Most of the secondary fibers cross at the anterior 
white commisure and ascend via the spinothalamic tract to the thalamus 
as part of the classical pain tract. 
In addition to the classical spinothalamic tract, other spino tracts 
such as the spinoreticular, the spinocervical and possibly the ventral 
spinothalamic tracts may also be important in pain perception (63, 68) 
While ascending to the thalamus, these tracts send collaterals to 
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areas of the brain stem concerned with nociception giving the potential 
for much interaction, integration and reflex activity. 
Areas of the brainstem, such as periventricular diencephlon and 
periaqueductal gray, have been shown to contain opiate receptors and/or 
to originate long decending monoaminoergic fibers (nucleus raphe magnus; 
NRM) to the dorsal horn of the spinal cord (69). These descending 
pathways (raphe-spinal) synapse in an axo-axonic manner, possibly with 
the primary afferent fiber and/or the inhibitory interneurons, and 
thereby modulate pain information transmission from these fibers (69). 
The simplest hypothesis is that these inhibitory interneurons are 
activated by these descending medullospinal pathways (e.g., raphe-
spinal). Supporting this hypothesis is the evidence that naloxone 
blocks the analgesia produced by electrical stimulation of the NRM and 
partially blocks NRM—induced inhibition of dorsal horn cells (69). This 
system is one of the brain's pain-modulating mechanisms and links the 
midbrain, medulla, and spinal cord. 
Recent studies show the presence of mu and delta receptors on the 
primary afferents (70). The existence of these does not necessarily 
indicate physiologically relevant receptors (71), yet the potential 
sites for opioid action are indicated. Kappa receptors on the primary 
afferents have not yet been demonstrated, although Gouarders (72) has 
demonstrated binding in the spinal cord. 
Analgesia 
Analgesia is a decrease in the perception of discomfort from pain, 
although it is not always successful in the partial or complete 
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eradication of that perception. Ideally, analgetics should not cause 
mental cloudiness or any other physical abnormality such as a decrease 
in respiration rate or sedation. In long term use of high dose narcotic 
analgetics8 patients usually tend to develop a tolerance to the negative 
effects relative to the analgetic effects. This is the case in the 
clinical reports on the maintenance of the relief of the chronic and 
intractable pain of cancer patients. 
Although it is often said that analgetics cause respiratory 
depression, mental confusion, and excitability in cancer patients, it 
has been documented that the pain is able to balance these negative side 
effects associated with short terra use of analgetics (73). 
STATEMENT OF PROBLEM 
The purpose of this research project was to delineate the 
structure-activity relationships of the keto moiety and the amino 
substituents in the aminotetralin analogues to opioid activity. In 
addition, the relative contribution to activity of the aromatic methoxy 
or hydroxy group would also be evaluated. 
To accomplish this, it was decided that the seven target compounds 
in Table 1, represented by Structure VI, would be synthesized. Compound 
F had been synthesized previously. The following discussion will 




Substituents of Aminotetralins 
Compound Rj ^2*^3 
F -OCH3 -H =0 
I -OH -H =0 
H -OCH3 -CH3 =0 
J -OH -CH3 =0 
G -OCH3 -H -H,(-H) 
K -OCH3 ~CH3 
L -OH -CH3 -H,(-H) 
SYNTHESIS OF THE COMPOUNDS 
The synthesis of these compounds was to follow the procedures given 
in a personal communication from Dr. P. Janssen relating to certain 
9,9-dimethylbenzomorphans which he had previously reported (74). The 
established synthetic procedures would be followed with few modifica­
tions. The proposed method, as briefly summarized in Scheme I, entailed 
starting with para-methoxyphenyl-acetic acid, converting it into the 
methyl ester (A) and by running a Reformatsky reaction on that ester, to 
form the keto-ester (B). This compound would then be reductively 
aminated by treating it with benzylaraine in refluxing toluene and 
azeotroping off the water to form the inline (C) which would then be 
hydrogenated to give the free aminoester (D). The amino ester would 
then be heated with 50% aqueous KOH, thereby converting it to the 
corresponding amino acid (E). Once isolated, the amino acid would 
cyellzed with polyphosphoric acid. This reaction would produce « y 
intermediate compound F (3—amino-2,2-dimethyl—7-methoxy 1 tet 
Compound F, which had been synthesized previously in the 
laboratories of the Medicinal Chemistry Department of this university, 
would be the common intermediate for this synthetic sequence (Sch 
II). Once obtained it would be converted to the HC1 salt. This 
compound would then be O-demethylated by use of BBr3, thus providi g 
3-amino-7-hydroxy-2,2-dimethyl-l-tetralone (compound I). Compound F 
will also be converted into the dimethylamino substituted co.p 
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O-demethylated to give the phenolic (7-OH) compound J. The reduction of 
the carbonyl group on compound F would give compound G, which is another 
key intermediate for synthetic routes to be performed. Compound G would 
then be dimethylated to give compound K, (3-dimethylamino-2,2-dimethyl-
tetralin), which in turn would be subsequently O-deraethylated to the 
phenolic compound L. 
The pharmacology would then be done on these compounds in an 
isolated tissue preparation. Evaluation of structure activity 
relationships would then be made. 
MATERIALS AND METHODS 
Instrumentation 
Melting points were done on a Hoover melting point apparatus in 
open capillaries and are uncorrected. The melting point of I:HBr was 
done on a Kofler Micro Hot Stage melting point apparatus and is 
uncorrected. 
Infrared spectra were done either in AgCl cells (Wilks) or as the 
KBr pellets prepared with the Carver press, and were run on a Perkin-
Elmer model 283 continuous grating spectrophotometer. Parameters are as 
shown on the individual spectral recordings. Nuclear magnetic resonance 
(NMR) spectra were done on a Varian XL—200 spectrometer, in a 5 mm 
broadband (switchable) probe, using an internal computer generated 
reference based on the solvent protons. Parameters are shown with 
individual spectra. The NMR spectrum of J was done on a Varian XL—400 
spectrometer. 
Mass specta were done at the National Institutes of Health (NIH), 
Bethesda, MD. Most were obtained by chemical ionization (CI) and were 
done on a Finnigan 1015D. Those done by electron ionization (EI) 
methods were run on a Hitachi RMU-6E (70ev) and are noted as such. 
Elemental analyses (C, H and N) were performed at the micro-
analytical laboratory of NIH. 
All TLC plates were Merck F-254 (5760-2), 5 x 10 cm, silica layer 
0.25 mm thick. Visualization, unless otherwise mentioned, was 
accomplished by UV light. 
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All solvents were of reagent grade quality unless otherwise noted. 
The water was double distilled and run through a Nanopure^ system. The 
tetrahydrofuran (THF) used in reactions was freshly distilled from a 
solution of sodium and benzophenone. 
Experimental 
Methyl 4-Methoxyphenylacetate (A). A solution of 150 g (0.90 mol) 
of 4-methoxyphenyl-acetic acid (Aldrich Chemical Co.) in 1.0 L of 
spectral grade MeOH (Eastman) was saturated with HC1 gas, then stoppered 
with a drying tube and stirred for 72 hours. The volume of solvent was 
reduced on a rotory evaporator, the pH of the solution was adjusted to 
6.0 with NH4OH and the remaining volatiles removed under vacuum. The oil 
remaining was distilled to give 142.8 g (88% yield) of the ester A, bp -
110°C at 0.250 mm Hg. 
Ethyl 2,2-Dimethyl-3-keto-4-(p-methoxyphenyl)butyrate (B). Prior to 
the reaction, reagent grade zinc granules were cleaned by treating them 
with a 9:1 solution of concentrated H2S0£ and concentrated HN03> rinsing 
thoroughly with distilled H20, and then acetone/H20. The cleaned zinc 
was dried by placing it in an oven and then stored in a vacuum 
desiccator. 
A mixture of 50 mL of THF, 22.7 g of Zn and 0.1 g of iodine were 
combined in a 3000 mL flask under N2 and gently refluxed. A solution of 
76.1 g (0.39 mol) of ethyl 2-bromoisobutyrate, 54.0 g (0.39 mol) of the 
methoxy ester A and 50 mL THF was added dropwise to the refluxing 
reaction mixture at a rate to maintain turbidity, kithin 3 to 5 hours 
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the starting materials had disappeared from the reaction mixture (TLC), 
and the reaction was considered to be complete. The reaction mixture 
was cooled and acidified to pH * 2—3 with 4N H2SO4 and the solvent 
removed under vacuum. Ester B was isolated by vacuum distillation which 
gave 97.0 g (0.37 mol, 94% yield) with a bp = 145-155°C at 1.0 mm Hg. 
Ethvl 3-Benzylimino-2,2-dimethyl-4-(p-methoxyphenvl)butvrate (C). 
Into a 1 L flask fitted with a Dean Stark trap and a condenser with a 
drying tube, 97.0 g (0.37 mol) of B were dissolved in 300 mL of 
technical grade toluene. A solution containing 41.0 g (0.38 mol) 
benzylamine (Aldrich) and 0.75 mL boron triflouride etherate (Eastman) 
in 50 mL toluene were added and the resultant mixture was refluxed. 
After 16 hours, 6.5 mL of water had accumulated in the Dean Stark 
trap. An additional 19.0 g of benzylamine and 1.5 mL of 48% HBr in 
glacial acetic acid were added, and the refluxing was continued. After 
3 hours the total water in the Stark trap was 13.0 mL. The reaction 
mixture was then cooled, washed with 10% NaHC03, and dried over MgS04. 
The toluene was removed on the rotary evaporator and the crude product 
was distilled at 145-155°C at 0.150 mm Hg, giving 95.6 g of compound C 
as an oil (0.27 mol, 73% yield). 
Ffhvl g-Amino—7-2 d i m e t h y l - A-fp—methoxvphenvl )butyrate ("l- Int° 3 
Parr bottle containing 150 mL of glacial acetic acid, 95.6 g (0.27 mol) 
of C were dissolved and 0.5 g Pt02 added. The solution was placed on 
the Parr Hydrogenation apparatus at initial H2 pressure of P 
After 8 hours 1.0 g of 10% Pd/C was added and hydrogenation continued. 
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After 96 hours, hydrogenation was stopped and the catalyst removed by 
vacuum filtration. The acetic acid volume was reduced to 1/5 its 
original volume under vacuum. The remaining solution, which was made 
basic (pH=10) with 50% aqueous KOH, was then extracted twice with Et20 
(75 mL) and then twice with CH2CI2 (75 mL).. The combined extracts were 
dried over MgSO^, filtered, and the solvent removed under vacuum. Vacuum 
distillation of the crude oil gave 50 g (0.19 mol, 70% yield) of amino 
ester D, bp = 125-129°C at 0.025 mm Hg. 
The free base D (50 g) was dissolved in 300 mL dry Et20, then HC1 gas 
bubbled in until crystal formation ceased. The solution was filtered, 
and the crystals were then washed with Et20 and dried under vacuum. This 
yielded 36.08 g (0.12 mol, 63% yield) of D:HC1^ rop = 136°C. 
3-Amino-2,2-dimethy1-4-fp-methoxyphenyl)butyrate (E). The 36.08 g 
of D:HC1 were dissolved in 300 mL of distilled H2O, and 0.14 mol KOH 
were added along with enough MeOH (approximately 50-75 mL) to keep the 
amino ester in solution. The reaction solution was refluxed for 
72 hours, then neutralized with concentrated HC1 to a pH of 7 and 
concentrated.under vacuum. The amino acid precipitated upon addition 
of distilled water, and was isolated by filtration to give 25.63 g 
(0.11 mol, 92% yield). The amino acid was recrystallized twice from 
water to give 20.23 g of pure crystalline E, mp = 207-209°C. 
3-Amino-7-roethoxy-2,2-dimethyl-l-tetralone (F). A boiling water 
bath was used to heat a bottle of polyphosphoric acid (PPA). Once the 
PPA had liquified sufficiently, 25 gra were placed in a round bottom 
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flask and agitated using mechanical stirring. The flask was replaced in 
the water bath and the temperature monitored. When the PPA had reached 
lOO^C, 14.0 g of E (0.06 mol) were added slowly. Heating and stirring 
were continued for 2 hours. The mixture was cooled by adding 500 g of 
ice and 250 mL of H20. The resulting mixture was basified to pH » 
10-10.5 with solid K0H and extracted with four 500 mL portions of CHCI3. 
The combined extracts were evaporated under vacuum; the remaining oil 
was distilled to give 9.9 g (0.045 mol, 76% yield) of amino tetralone F, 
bp = 133-145°C at 0.10 ram Hg. 
Anal. C13H18N02C1 (M.W. = 219.29); 
Calcd. C, 61.05; H, 7.09; N, 5.48; 
Found C, 60.76; H, 7.32; N, 5.65. 
Mass spec CI M+l = 220. 
See IR Fig. 2 and NMR Fig.. 3. 
3-Dimethylamino-2,2-diraethyl-7-methoxy-l-tetralone (H). A solution 
of 3.0 g (13.68 mraol) of F and 4.04 g (78.5 mmol) of 90% formic acid 
were mixed in a 50 mL flask at room temperature, then warmed gently at 
35-40°C until clear. To this solution 34.2 mmol (3.02 g) of 35% 
formaldehyde were added dropwise, with continuous stirring. 
A drying tube and condenser were attached to the reaction flask 
and the solution was heated to 100°C. Evolution of C02 began almost 
immediately and continued for nearly 90 minutes. Heating and stirring 
were maintained for 12 hours, then the reaction mixture was removed from 
the hotplate and cooled. To the cooled reaction mixture were added 
100 mL of 5% HC1, and the solvent removed under vacuum. To the dried 
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residue were added 50 mL of 5% HC1 and the acidic solution was washed 
3 times with 50 raL portions of CH2CL2. The solvent was removed under 
vacuum on the rotary evaporator, then 100 mL of distilled H2O were added 
to the resultant oil, and this solution was basified with NaOH pellets 
(pH = 11). This was extracted with five 50 mL portions of CHCI3. The 
combined CHCI3 extracts were dried over K2CO3, filtered, and the solvent 
removed under vacuum. The crude yield of H was 2.621 g (10.6 mmol, 
77.5% yield) as a viscous amber oil. Final purification of H was 
accomplished by column chromatography. A 50 mm x 1000 mm chromatography 
column was packed with a 70-260 micron silica gel, and eluted with a 
80:19:1, cyclohexane, isopropanol and ammonia hydroxide solution. The 
melting point of the eluted product (2.29 g, 59.1% yield) as the HC1 
salt was 126-128<JC. 
Anal. Ci5H22N02Cl*H20 (M.W. = 247.34): 
Calcd. C, 59.69; H, 8.02; N, 4.64; 
Found C, 59.93; H, 8.49; N, 4.41. 
Mass Spec, CI, M+l» 248. 
See IR Fig. 6 and NMR Fig. 7. 
3-Dimethvlamino-7-hvdroxv-2.2-dimethvl-l-tetralone (I). In a 25 mL 
round bottom flask under a N2 atmosphere, 0.300 g (1.14 mmol) of t was 
added to 7.00 mL of 55% HBr and the resultant solution was refluxed for 
5 hours, at which time all starting material, as monitored by TLC, was 
gone. The reaction mixture was allowed to cool and maintained under a 
steady flow of N2. At this point, some crystals of the HBr salt of I 
(63 mg, 19.3% yield) were filtered off. To the filtrate were added 3 mL 
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of distilled H2O (pH of the solution was approximately 3). The solution 
was warmed to 50°C, 0.5 g activated charcoal was added, and the solution 
was filtered. The filtrate was basified with concentrated NH4OH and 
allowed to evaporate at ambient conditions. The crystals, which had 
formed after 7 days, were isolated by filtration and dried to give 81 mg 
(35% yield) of the zwitterionic form of compound I. Total combined 
yields of both products was 55%. 
Anal. ^12^15^2 (M.W. * 205.26); 
Calcd. C, 70.22; H, 7.37; N, 6.82; 
Found C, 69.96; H, 7.64; N, 6.60. 
Mass Spec, CI, M+l - 206. 
See IR Fig. 4 and NMR Fig. 5. 
3-Diroethylamino-7-hvdroxy-2.2-dimethyl-l-tetralone HBr (J). In an 
atmosphere of N2, 1.8 g of H (7.18 mmol) were added to 2.5 g (14.4 mmol) 
of 48% HBr, and the resultant mixture was refluxed for 48 hours. The 
solution was cooled and the crystals which had formed were isolated by 
filtration. This gave 1.45 g (4.62 mmol, 64% yield) of J:HBr, mp 
268-273°C. The product was taken up in distilled H2O, treated with 
activated charcoal, filtered, and allowed to recrystallize under 
standard room conditions. This procedure gave 1.32 g (58% yield) of 
J:H8r, mp = 271-274°C. 
Anal. C!4H2oN02Br (M.W, = 233.31): 
Calcd. C, 53.53; H, 6.42; N, 4.46; 
Found C, 53.64; H, 6.22; N, 4.49. 
Mass Spec, CI, M+l — 234. 
See IR Fig. 9 and NMR Fig. 8. 
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3-Diroethylamino-7-methoxv-2,2-dimethyItetralin (K) . A mixture of 
30.0 mL glacial acetic acid, 1.0 mL perchloric acid, 0.10 g of H 
(0.404 mrnol) and 0.20 g 10% Pd/C were placed in a Parr hydrogenation 
apparatus and heated to 40°C at 50 psi of H2. After seventy-two hours 
hydrogen uptake had ceased. The reaction was filtered to remove the 
catalyst and the volume of the solvent was reduced iji vacuo. The solu­
tion was basified with a saturated solution of NaHCOj and then extracted 
with two 30 mL portions of CHCI3. The combined CHCI3 extracts were taken 
to dryness under vacuum. The resulting oil was dissolved in 30 mL of 
dry Et20, and saturated ethereal:HC1 solution was added until no further 
crystals precipitated. Recrystallization from a minimal amount of warm 
EtOAc yielded 0.068 g (0.252 mrnol, 62%) of K:HCL; mp = 145-147°C. 
Anal. C15H23N0 (M.W. = 233.35); 
Mass Spec, CI, M+l = 234. 
See IR Fig. 10 and NMR Fig. 11. 
3-Dimethvlamino-7-hydroxv-2.2-dimethvltetralin HBr (L). Under a N2 
atmosphere, 40 mg of K (0.17 mmol) were dissolved in 1.5 mL of 48% HBr 
and heated at 102°C for 16 hours. The solvent was removed by mild heat­
ing (35-40°C) and maintaining a steady flow of N2. To the resultant oil, 
2 drops of H2O and 0.5 mL of EtOH were added. After allowing the mixture 
to cool for 90 minutes, 3 volumes of THF were added and then the resultant 
solution was refrigerated for 48 hours. The cold mixture yielded 18 mg 
(0.0599 mol; 48.3%) of L:HBr crystals by decantation; mp = 253-256°C. 
Anal. Ci4H2iN0 (M.W. = 219.32); 
Mass Spec, CI, M+l = 220. 
See IR Fig. 12 and NMR Fig. 13. 
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3-Amino-2,2-dimethyl-7-methoxytetralin (G) . Into a Parr 
hydrogenation bottle were placed 100 mg of F (0.4560 mmol), 50 mL of 
glacial acetic acid and 5 drops of perchloric acid. The bottle was 
flushed with argon and 250 mg of 10% Pd/C were added to the mixture. 
This was placed on a Parr hydrogenator at 60 psi of H2» covered with a 
heating jacket and warmed to 45°C. After 100 hours of hydrogenation, 
the reaction was stopped, allowed to cool to room temperature, and the 
catalyst was removed by filtration. The filtrate was evaporated under 
vacuum until a thick viscous oil remained. The oil was dissolved in 
5 mL of H2O and basified to pH = 10-10.5 with concentrated NH4OH 
solution and extracted with three successive 10 tnL portions of CHCI3. 
The extracts were dried over Na2S04, filtered, and the solvent was 
evaporated in vacuo to 1/3 of its original volume. The solution was 
allowed to stand at atmospheric conditions until crystals formed 
(12-20 hours). Once crystals had formed, they were isolated by filtra­
tion and dried under vacuum to yield 19.0 mg (20% partial yield) of G» 
mp = 120-122°C. The filtrate was evaporated to dryness under vacuum. 
The material left in the flask was dissolved in 25 mL Et20 and carefully 
acidified with ethereal:HC1 solution. Once crystal formation ceased, 
the solution was filtered and the solid obtained was dried to afford 
G:HC1; 0.061 g (51,72% yield), mp = 213-215°C. Total yield of G and 
G;HC1 = 71.72%. 
Anal. C13H19NO (M.W. = 205.29); 
Mass Spec, CI, M+l = 206 
See IR Fig. 14 and NMR Fig. 15. 
RESULTS AND DISCUSSION 
Chemistry 
The synthesis of intermediate F did not proceed as readily as 
anticipated. The reductive amination of compound B to compound C 
resulted in significantly lower yields than previously reported. After 
numerous syntheses of compound C, minor procedural changes were insti­
tuted and the reaction was closely monitored by TLC observations. An 
average purified yield of 45% was obtained, but only with the most 
assiduous effort. Normally the crude yields ranged from 40-65%, 
depending on the length of time the reaction was re fluxed. 
The only other synthetic step which caused any significant problem 
was the hydrolysis of D and subsequent isolation of the amino acid E. 
The rigors of isolation and purification of an amino acid can be a very 
unique and difficult problem. In this case, the isolation of E was 
especially difficult because its precursor ester (D) had not previously 
been isolated from the hydrogenation reaction mixture in the synthetic 
sequence on which the production of compound F was based. Consequently, 
the hydrolysis reaction mixture contained impurities which interfered 
with the isolation of the amino acid (E). Any quantity that did form 
was not a. significant amount, nor was it pure. To overcome this 
problem the amino ester (D) was isolated and purified by fractional 
distillation, following the catalytic hydrogenation. Further 
purification was done by making the D:HC1 salt and recrystallizing. 
When only one spot was detectable by TLC, the D:HC1 was then hydrolyzed 
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in nearly quantitative yields (>90%). The initial product (compound E) 
isolated was relatively clean (by TLC). Further purification by 
repetitive crystallization resulted in very fine needle-like crystals 
which did not show a discernible difference in the melting point. 
Cyclization of the amino acid (E) in polyphosphoric acid (PPA) yielded 
crude F in fairly consistent yields of 80-90%. 
In light of the fact that all of the compounds preceding F had been 
previously synthesized in the Medicinal Chemistry Department at UOP, 
their spectral data will not be discussed here. Since compound F was a 
common intermediate for the synthesis of all further compounds, it is 
used as the point of reference regarding spectral interpretations. 
In the IR of F (Fig. 2) the major absorbances seen are the amine 
stretching at **3500 cm-^ and amine bending at **1580 cm the aromatic 
stretching region at **3030 cm-^ and in—plane skeletal vibrations at 
1600 cm-^; and a relatively sharp but wide aliphatic stretching region 
at -3000-2500 cm"1. The expected carbonyl stretching absorption 
appeared at -1690 cm'1, and the multiple bond stretching absorption due 
to the gem methyl groups at -1385 cm-1. 
The NMR of F (Fig. 3) cleanly exhibited all the expected 
absorbances. The gem methyl protons appeared at 0.9 and 1.7 ppm. The 
protons on C-4 (Structure VI) show as a double-doublet at 3.4 and 3.6 
ppm. In this spectrum, solvent peaks for CD3OD occurred at 3.5 
(quintuplet) and 4.4 ppm (singlet). Buried on the upfield side of the 
tall singlet at 3.85 ppm, which are the methoxy protons, is the proton 
alpha to the primary amine at 3.7 ppm. The aromatic protons appeared at 
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7.0-8,0 ppm. The integrations were in agreement with the above assign­
ments. Once isolated and purified, F was stored as the free base. Care 
was taken to store F under a dry inert atmosphere, otherwise it would 
begin to slowly decompose. It was necessary on several occasions to 
fractionally redistill F to remove the breakdown material. As would be 
expected, the HC1 salt was a more stable form, although not readily 
usable for certain reactions. 
The demethylation of F to create compound I presented a major 
stumbling block. A contemporary method, elucidated by Kenner Rice (75) 
in the conversion of codeine to morphine, was originally attempted with 
seemingly no results. Alternative methods were investigated, one such 
being a reaction using methylsulfonic acid and methionine. A very low 
yield of 20-30% (of I) was obtained but proved invaluable as a TLC 
reference for another large-scale attempt with BBr3. Once again very 
low yields were obtained (20-30%), but the product was identical to the 
methionine-methylsulfonic acid reaction product as seen on TLC. This 
was not a sufficient amount for pharmacological testing. When the 
classic 0-demethylation reaction of refluxing with concentrated HBr was 
employed, exemplary results occurred. Refluxing overnight under a 
steady flow of N2 rendered an I:HBr product in 20% yield. The mother 
liquor was basified with concentrated NH4OH and allowed to evaporate 
over the next 7 days, resulting an additional 35% of the zwitterionic 
free base. The total yield was twice that produced by the previous 
reactions. Compound I was originally isolated as the HBr salt, and 
an unusually high melting point > 300°C. Using a micro hot stage 
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melting point apparatus, a melting point of 335-338<>C was observed. 
The C, II and N analysis was done on the lower melting free base 
(mp = 182-184°C). The analysis was within ± 0.4% of the calculated 
values. Mass spectrometry was done on both the free base and HBr salt. 
Both analyses gave M+l ion 206, MW = 205.26. 
The IR spectrum of I (Fig. 4) exhibited all the peaks found in the 
IR of F with the noticeable addition of a sharp downfield absorbance 
"3400-3200 cm-l, which could be due to the phenolic moiety. The NMR of 
compound I (Fig. 5) was run in D2O, and the spectrum appeared very 
similar to that of F, but the singlet at 3.8 ppm (-GCH3) was gone, as 
expected. The peak pattern in the aromatic region (7.0-8.0 ppm) was 
changed but the integration remained the same. 
The N-dimethylation of F was originally attempted by reductive 
methylation using NaCNBH3 and H2CO. This procedure afforded two 
products, probably the monomethyl amine and the dimethyl amine. Since 
the composition of the.products isolated from reaction was a mixture of 
the secondary and tertiary alkyl amines, and the overall yield of all 
products from the reductive amination was only "43%, the Eschweiler-
Clarke method for dimethylation of the primary amine (F) was successfully 
employed with little difficulty until the workup procedure. The 
formaldehyde present was a contaminant that was tenacious to wash free 
from the product in almost any solvent. Even distillation did not 
afford a pure product. Column chromatography was employed for final 
purification of compound H. The column was packed with 350 g silica 
gel (60-250 microns, [J. T. Baker]) and eluted with an 80:19:1 
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cyclohexane, isopropanol, and concentrated ammonia solution. The 
recovered H (2.0 g) was converted to the H:HC1 salt. The IR of H 
(Fig. 6) showed a significant increase in absorbance for the amine 
moiety at **3650 cra~l due to the dimethyl groups. These methyl groups 
tend to shift that peak upfield. All other major peaks were accounted 
for as previously mentioned. 
The NMR of H:HC1 in CD30D (Fig. 7), unexpectedly showed the 
N-dimethyl groups as two small singlet humps, one at ~2.0 ppm and the 
other at 2.6 ppm. Two obvious differences in the NMR spectra of H as 
compared to that of F are that: 1) the gem methyl group peaks appeared 
as a single peak absorbing at 0.95 ppm, and 2) the 2 protons at C-4 
(Structure VI) no longer appeared as a double-doublet, but as a singlet 
at 3.2 ppm.: It is possible that the solvent peak had some smaller peaks 
buried in the bottom right and left of the peak. Compound H was the 
only product in which C, H and N analyses indicated a monohydrated 
product. The mass spectrum ion M+l equalled 248 (M.W. = 247.34). 
The first attempt at O-demethylation of H to produce J was done 
using BBrj in CHCL3. This experiment was the deciding point of whether 
or not this reaction showed any merit for O-demethylation in this series 
of aminotetralin compounds. Again, as in the previously mentioned 
procedure for converting F to I, the yield was unacceptably low (30-38% 
crude product). Analogous to what was done for I, compound H was placed 
in a reacti-vial with 48% HBr, sealed under a dry atmosphere of nitrogen, 
and refluxed for 16 hours. The solution was reduced to half its volume 
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formation subsided. The J:HBr crystals were isolated in a 58% yield 
after two recrystallizations. Unfortunately, the solubility of J:HBr is 
only 2 mg/mL in D2O which is not an adequate concentration to take an 
NMR on the XL-200; therefore this spectrum was graciously run by George 
Grey at Varian Associates on their XL—400. The NMR of J:HBr (Fig. 8) 
was very similar to the NMR of H, and showed the gem methyl protons as a 
doublet at 1.2 ppm, the amino methyl groups as a single hump at 2.6 ppm, 
but the absorption due to the methoxy group at 3.6-3.8 ppm was lacking 
as expected. All of the other peaks were, observed at previously 
mentioned frequencies. The IR of J (Fig. 9) showed a weak absorbance 
at -3150 cm"1 for the phenolic group. No other significant changes 
were noted. All major peaks were accounted for as previously mentioned. 
The simple reduction of F to G (carbonyl to the methylene at C-l 
[Scheme II]) was attempted early on in this synthesis. Initial attempts 
at this reduction failed to give definitive results. The reaction 
mixture always showed multiple spots on TLC. Initially the reduction of 
F was attempted by catalytic hydrogenation with little apparent success. 
Liquid ammonia and sodium (or liquid ammonia and lithium) were tried, 
as was the LAH-AlCl3-lemonine reaction, again yielding no definitive 
products. It was decided to circumvent G and attempt instead the 
conversion of H to K. 
Compound H was catalytically hydrogenated to yield compound K. The 
free base was converted to the HC1 salt and crystallized in a yield of 
62%. The IR spectrum of K (Fig. 10) showed a weak absorbance at -1725 
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starting material. This impurity also appeared on the mass spectrum 
as an M+l = 234+16. After subsequent recrystallization, the hrMR of K 
(Fig. 11) was run and the integration was accurate. The gem methyl 
groups appeared as a pair of singlets at 1.1 ppm and 1.3 ppm. The C-l 
protons appeared as the multiplet peaks between -2.45 ppm and 2.75 ppm, 
the furthest downfield being buried under the amino methyls at 2.8 ppm. 
All other peaks were as shown on the preceding NMR spectrum of compound H. 
Compound K was O-demethylated (as were F and H) using concentrated 
HBr under an inert atmosphere. After refluxing overnight the solution 
was concentrated to a viscous oil under vacuum. Water and EtOH were 
used to solubilize the reaction products, then THF was added to force 
the LrllBr out of solution. Because the yield was so low (18 mg), no 
recrystallization was attempted. 
The IR of L (Fig. 12) clearly showed the absence of the carbonyl 
group at -1725 car1. The NMR of L:HBr (Fig. 13) showed no methoxy group 
at 3.6 ppm as in the NMR of K. The amino methyl groups appeared as two 
singlets at -2.7 ppm and -2.9 ppm. Other than these two deviations, the 
NMR spectrum of L was nearly superimposable on that of compound K. 
Compound G was synthesized by the long term catalytic hydrogenation 
with a two-fold excess of 10% Pd/C in acetic acid (with 1% perchloric 
acid) and heating the hydrogenation mixture to 40-50°C. 
The IR of G:Base (Fig. 14) showed the primary amine at -3380 cnT1 
and the other major absorbances seen in the IR spectrum of F (Fig. 2). 
The carbonyl absorbance at -1780 cm"1 was gone, although a barely 
distinguishable blip at -1780 cm"1 was apparent from a minor contaminant. 
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The NMR of G:Base (Fig. 15) was run in CD3OD. The gem methyl 
groups were observed at 0.9 ppm and 1.1 ppm (some minor impurities at 
1.3 ppm). The next singlet at 2.6 ppm were the protons at C-l 
(Structure VI). The rest of the spectrum was the same as the other NMRs^ 
Pharmacology 
Preliminary testing of the compounds was done primarily by F3tima 
Matos in the Pharmacology Department at the University of the Pacific. 
All compounds were tested for agonist and antagonist capacity using the 
electrically—stimulated guinea pig ileum longitudinal muscle (in vitro) 
preparation. 
Male guinea pigs (400—600 g) were used to supply the ileum from 
which the longitudinal muscle was stripped, as per the procedure 
described by Kosterlitz et al, (75, 76). In a very general overview, 
the strip of longitudinal muscle was set up in a 5 mL isolated tissue 
bath (37°C) between two platinum electrodes. The bath contained a Krebs 
bicarbonate buffer solution. 
The muscle strip was connected to a transducer, and the isometric 
contractions, induced by electrical stimulation, were recorded on a 
Grass Model 7 polygraph. After the ileum reached equilibrium, the 
"compound" was added to the bath and left in contact with the tissue 
until maximal effects had been reached or three minutes had passed. 
The preparations were then washed until equilibrium contractions had 
been regained, ranging anywhere from 30-60 minutes between doses. 
Dose-response data were taken and linear regression analyses were done 
on a Hewlett-Packard model 86B computer using Hewlett Packard HP-83/85 
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Fig. 16 is a plot of percent inhibition of the electrically 
stimulated contraction vs the concentration of "compounds" given in 
micromolar. The information is also presented in tabular form in 
Table 2. Generally this class of drugs (compounds) did not show a 
significant degree of potency in comparison to normorphine (NM),. 
They ranged from 1/40 to 1/1000 the potency of NM, generally averaging 
approximately 1/700. In comparison to EKC, they were an additional 
10-fold less potent. Although the compounds were weak agonists they 
were (with the exception of I and G) still able to exhibit anywhere 
between 60 and 85% inhibition, which is not significantly different 
from the maximum effects of NM at 72% and EKC at 71%. The most potent 
of the seven compounds synthesized was J (3-dimethylamino-7-hydroxy-
2,2-dimethyl-l-tetralone). 
It has been generally observed in opioid compounds that optimum 
activity is achieved when the C-7 group (Structure VI) is converted from 
a methoxy to a hydroxy group. With the conversion of compound F to 
compound I (Scheme II), nearly a 7-fold decrease in potency was seen in 
addition to a corresponding decrease in maximal effect (inhibition). 
This same phenomenon was seen in the O-demethylation of compound K to 
compound L, although somewhat less significant, on the order of a 25% 
decrease in potency coupled with a 32% decrease in maximal effects. The 
only compound that elicited the expected increase in response was J, the 
increase in potency on the order of five-fold and approximately a 20% 




Activity of Various Substituted 3-Amino-2t2-dimethyltetralins 
in the Guinea Pig Ileum Longitudinal Muscle Preparation 
Calculated by Linear Regression 
IC50 % Maximum 
Compound N (uM) Slope r Inhibition 
F 22 77.37 54.08 0.90 71 
I 20 578.03 37.14 0.78 29 
H 24 75.35 50.41 0.82 68 
J 46 4.20 32.07 0.64 85 
G 9 217.33 53.23 0.92 45 
K 30 54.55 57.09 0.78 75 
L 29 69.81 27.74 0.53 57 
NM 145 0.10 38.37 0.72 72 
EKC 75 0.02 40.44 0.73 71 
IC50 = concentration for 50% inhibition of the maximum response 
calculated from the regression line equation. 
r = Correlation coefficient. 
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Even though the maximal effect and potency varied in the phenolic 
compounds, it is interesting that all of them exhibited similar slopes, 
apparently different from their methoxy precursors. 
Small alkyl substituents on the amino group generally elicit a 
change in both potency and maximal effect, although when compound F was 
dimethylated to compound H, negligible changes in either potency or 
maximal effect were seen. In the alkylation of compound G to K, amino 
substitution accounted for a 65% increase in maximal effect and a 
compound with 4 times the potency. Evaluating compound I with respect 
to compound J, the dimethylation exhibited the most significant changes 
seen in this series of compounds. The maximal effect of J was nearly 
185% greater than that of compound I, and over 150 times as potent. 
In trying to determine the site of action of these "compounds," 
experiments were done where the compounds were challenged by an 
antagonist (naloxone). It has been shown that low concentrations of 
naloxone, e.g., a 100-300 nanomolar dose, will preferentially inhibit mu 
receptor mediated agonist activity. In higher doses (500-1000 nanomolar), 
inhibition of both mu and kappa receptor mediated agonist activity should 
occur (78). Incubation time in the antagonism experiments for the 
naloxone challenge of J was 3 minutes and 5 to 10 minutes for the other 
compounds. The results of these experiments are shown in Table 3. 
Since a low dose of naloxone inhibited virtually all of the agonist 
activity of J, this would suggest that its effects are being modulated 
through the mu receptor. When all of the other compounds were tested 
their agonist effects were only partially blocked by the naloxone 
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Table 3 
Agonist Capacity of Aminotetralin Derivatives 
Blocked by a Naloxone Challange 
Compound N Naloxone HC1 % Blockade 
(nM) By Naloxone 
NM 8 176 90 
J 10 176 80 
EKC 7 704 97 
I 5 704 52 
F 8 704 30 
H 8 704 29 
G 3 704 0 
K 9 704 14 
L 8 704 38 
62 
challenge, at a dose large enough to antagonize both mu and kappa 
receptor agonists. The implications of this type of response cannot 
be unequivocally stated based on only one type of assay method and 
challenged by a single antagonist. 
Antagonist Experiments 
A limited number of experiments were done with moderate doses 
(5-10 nanomolar) of the compounds to test for their ability to 
antagonize normorphine and ethylketocyclazocine. Compound F partially 
blocked normorphine, the prototype mu (u) receptor agonist, but did not 
antagonize ethylketocyclazocine, the prototype kappa (k) receptor 
agonist. In addition, compounds I, H, and J showed no antagonist 
capacity on either mu or kappa receptors, at these doses. 
CONCLUSION 
A series of aminotetralin compounds were synthesized and shown to 
have weak to moderate opioid activity. It was demonstrated that for 
specific mu-raediated agonist activity in 3-amino-2,2-dimethyltetralin 
compounds, the amine must be alkylated, the C-7 group must be in the 
phenolic form and there must be a carbonyl group at C-l, as in compound 
J. Any analogues which deviated from the above characteristics resulted 
in compounds that appeared to exert a significant portion of their 
agonist effects through kappa-opioid receptors and/or other undetermined 
receptor sites. Compound K (3—amino—2,2—dimethyl—7-methoxytetralin) 
exhibited the second highest maximal effect and the second lowest IC50 
in this series of compounds. However, only 14% of its inhibitory effects 
(agonist activity) could be attributed to the kappa receptor. This 
was determined by a 704 nanomolar challenge of naloxone* which in the 
GPI assay was capable of antagonizing the effects of EKC by 97%. The 
importance of this observation is that the compound was able to exhibit 
effects which were nearly analogous to those of NM or EKC, but by means 
of another opioid or a non-opioid receptor. Compound G was not a very 
potent compound. Its maximum effect was approximately 50% inhibition, 
yet 100% of that effect was mediated through some receptor site other 
than the opioid mu and kappa. It appeared that the lack of a C-l 
carbonyl group combined with a methyl ether at C-7 seemed to direct 
away from the mu and kappa receptor sites. The methyl ethers (F, H, G 
and K) exhibited no measurable mu effects; however, they showed varying 
63 
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percentages of kappa effects. Nearly all of the^ r 
y ot these compounds had the 
same slope when determining the IC*n Th« -i • 
8 cne ic50. The phenolic group substituent 
at C-7 generally increases activity and potency. The pharmacological 
effects of compound J support this generalization. Demethylation of the 
methyl ethers to a phenolic group resulted in compounds with decreased 
activity and potency (I and L). This discrepancy was observed by Martin 
C20) in in vivo studies on other aminotetralins. Thorough binding 
studies will be needed to establish the importance of this observation. 
The diversity of pharmacological effects elicited by aminotetralln 
compounds was discussed by Cannon (79), who illustrated the numerous 
sites of action where they may be capable of binding, 
There exists no assay that is able to predict all the effects 
and liabilities of a compound in humans or in different animal models, 
although many improved methods of testing pharmacologic agents have 
been developed in the past decade. The GPI assay which was used for 
preliminary pharmacological testing of these compounds is a very 
sensitive assay. The findings from the GPI must be augmented with 
other in vitro and in vivo assays. The capability now exists to 
delineate better the site of action of opioids. Selective receptor 
blockade experiments and/or experiments using multiple antagonists (of 
different known receptors) would readily contribute to a better 
understanding of the specific receptors involved. 
There are currently many theories on the type (nature) of the 
opioid receptor(s). The more commonly accepted idea basically states 
that there are distinct multiple receptor sites. The findings of this 
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research project substantiate but also question this idea. Based on the 
nature of these ligands, that they are all small synthetic modifications 
of 3-amino-2,2-dimethyltetralins with some type of oxygen substituent at 
C-7, and that the molecular size doesn't vary greatly, it would be 
reasonable to assume that they would all interact with the same receptor 
site. This is not to suggest that they would all bind in the same 
manner at the given receptor., just at the same receptor. If this were 
true then the experiments done with the naloxone challenge should have 
been able to antagonize all of the effects of all the compounds. This 
of course was not what was observed. Because the location(s) of action 
(of the compounds that were not antagonized by naloxone) was not 
identified, it is not obvious whether the effects are from a subclass of 
opioid receptor or another physiological/pharmacological receptor site* 
If future studies demonstrate that the effects were opioid, then this 
study suggests the nearly identical structure of the different 
receptors. If it is determined that the resultant agonist effects 
(those not blocked by naloxone) are from a non-opioid receptor, than 
information pertaining to the "other receptor(s)" would be gained and 
help explain some of the "side effects" caused by the direct action 
(binding) of the drug. Also if this second hypothesis is the case, than 
in regard to the opioid receptor site it could be stated that the effect 
of the compound is mediated by the position in which it bands within a 
three-dimensional receptor site. 
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